Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:16
|
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [41] Tumor immunogenicity status in high-grade serous ovarian cancer
    Berry, Laurel
    Kelly, Michael
    Miller, Lance
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S319 - S319
  • [42] Novel strategies for targeting high-grade serous ovarian cancer
    Perets, Ruth
    Wyant, Gregory A.
    Ohman, Anders W.
    Setlur, Sunita R.
    Crum, Christopher P.
    Drapkin, Ronny
    Dinulescu, Daniela M.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [43] Describing intratumoural heterogeneity in high-grade serous ovarian cancer
    Nixon, K.
    Wulandari, R.
    Curry, E.
    Rama, N.
    Bowtell, D.
    Cunnea, P.
    Fotopoulou, C.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 87 - 88
  • [44] Defining the Molecular Footsteps of High-Grade Serous Ovarian Cancer
    Nagendra, P.
    Lombard, J.
    Jamaluddin, F.
    Tanwar, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 26 - 26
  • [45] Principles of dormancy evident in high-grade serous ovarian cancer
    Shepherd, Trevor G.
    Dick, Frederick A.
    CELL DIVISION, 2022, 17 (01)
  • [46] ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by epigenetic modification
    Huang, Jiazhen
    Tang, Ying
    Li, Yibing
    Wei, Wei
    Kang, Fuli
    Tan, Shuang
    Lin, Lin
    Lu, Xiaohang
    Wei, Heng
    Wang, Ning
    CELLULAR SIGNALLING, 2024, 116
  • [47] Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
    Konishi, Ikuo
    Abiko, Kaoru
    Hayashi, Takuma
    Yamanoi, Koji
    Murakami, Ryusuke
    Yamaguchi, Ken
    Hamanishi, Junzo
    Baba, Tsukasa
    Matsumura, Noriomi
    Mandai, Masaki
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (05)
  • [48] mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
    Musa, Fernanda
    Alard, Amandine
    David-West, Gizelka
    Giuroiu, Iulia
    Blank, Stephanie
    Pothuri, Bhavana
    Curtin, John P.
    Schneider, Robert
    CANCER RESEARCH, 2014, 74 (19)
  • [49] Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer
    Moran-Jones, Kim
    Gloss, Brian S.
    Murali, Rajmohan
    Chang, David K.
    Colvin, Emily K.
    Jones, Marc D.
    Yuen, Samuel
    Howell, Viive M.
    Brown, Laura M.
    Wong, Carol W.
    Spong, Suzanne M.
    Scarlett, Christopher J.
    Hacker, Neville F.
    Ghosh, Sue
    Mok, Samuel C.
    Birrer, Michael J.
    Samimi, Goli
    ONCOTARGET, 2015, 6 (42) : 44551 - 44562
  • [50] Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
    Machino, Hidenori
    Dozen, Ai
    Konaka, Mariko
    Komatsu, Masaaki
    Nakamura, Kohei
    Ikawa, Noriko
    Shozu, Kanto
    Asada, Ken
    Kaneko, Syuzo
    Yoshida, Hiroshi
    Kato, Tomoyasu
    Nakayama, Kentaro
    Saloura, Vassiliki
    Kyo, Satoru
    Hamamoto, Ryuji
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2023, 55 (10): : 2205 - 2219